Creative Medical Patent Approval for Diabetes Treatment: CELZ Stock on the Rise

Creative Medical Technology Holdings (CELZ) has secured a patent from the USPTO for a diabetes treatment using enhanced myeloid suppressor cells. The patent enables the company to develop a comprehensive cell-based immunotherapy strategy using the ImmCelzTM product. Analysts forecast an average target price of $20.00 with a potential upside of 698.44%. The estimated GF Value is $1.36, indicating a downside of 45.71% from the current price.

Creative Medical Technology Holdings, Inc. (CELZ) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application focused on treating Type 1 Diabetes using cell-based immunotherapy. The patent, which will be effective until at least 2040, covers the use of the Company's ImmCelzTM product, which utilizes supercharged T regulatory cells with proprietary cell-free solutions [1].

The technology has been validated using cells from Type 1 Diabetes patients and aims to address the autoimmune condition where the body attacks insulin-producing beta cells. The patent allowance aligns with the Company's ongoing CREATE-1 clinical trial and strengthens their intellectual property portfolio in regenerative medicine [1].

Creative Medical's ImmCelz platform utilizes a patient's own extracted immune cells, which are then "reprogrammed/supercharged" by culturing them outside the patient's body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes that this process endows the immune cells with regenerative properties, providing them with the ability to treat multiple indications [1].

The patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes, which is an autoimmune disease in which the body's immune system attacks and destroys insulin-producing beta cells in the pancreas. Because beta cells produce insulin, which is essential for moving glucose (sugar) from the blood into cells for energy, the destruction of these cells leads to a deficiency in insulin and the development of diabetes [1].

"We believe that the use of ImmCelz to prevent and/or treat Type 1 Diabetes is regenerative immunotherapy in its truest form,” said Timothy Warbington, CEO of Creative Medical. “The treatment of Type 1 Diabetes remains a primary focus for our Company, as evidenced by our ongoing CREATE-1 clinical trial. This issuance protects the integrity of our IP portfolio and reflects the potential of our cell-based therapeutic platform to address multiple unmet medical needs” [1].

Analysts forecast an average target price of $20.00 with a potential upside of 698.44%. The estimated GF Value is $1.36, indicating a downside of 45.71% from the current price [2].

References:
[1] https://www.stocktitan.net/news/CELZ/creative-medical-technology-holdings-receives-notice-of-allowance-xec0eh0g71vq.html
[2] https://www.stocktitan.net/news/CELZ/creative-medical-technology-holdings-receives-notice-of-allowance-xec0eh0g71vq.html